InSphero, a Swiss SME, announces together with the REPRINT project partners, Asgard Therapeutics, project coordinator, Lund University and Antineo, the achievement of proof-of-principle for using dendritic cell reprogramming to kick start in-vivo anti-tumor immunity.
Read moreAsgard Therapeutics announces appointment of three members Axel Schambach, MD PhD, Johanna Olweus, MD PhD, and Joshua Brody, MD to its Newly Formed Scientific Advisory Board (SAB).
Read moreAsgard Therapeutics was featured at the Nature Biopharma dealmakers new collection, highlighting companies developing innovative cell and gene therapies. Take a closer look at how Asgard’s in-vivo direct reprogramming approach can convert tumor cells into antigen-presenting dendritic cells and turn cold tumors hot.
Read moreFrom a collective of 40 selected start-ups, Asgard Therapeutics was awarded the runner-up prize as part of the NLSDays Investment Track.
Read moreLund, Sweden, 13 September 2022 – Asgard Therapeutics AB (“Asgard”), a private biotech company pioneering...
Read moreLund, Sweden – 01 June – Asgard Therapeutics AB (“Asgard”) today announces that the United States...
Read moreAsgard Therapeutics announces today that the Eurostars-funded project REPRogramming tumors INTo immune cells - a revolutionary gene therapy to treat cancer (REPRINT) - has officially kicked-off.
Read moreThe world wealthiest look for cellular reprogramming as the key for longevity with limitless funds for research
Read more